PPT-Prospects for imaging prostate cancer with PET/CT and PET/MR

Maurizio Conti Siemens Healthcare Molecular Imaging Knoxville Tennessee USA Mediterranean Thematic Workshops in Advanced Molecular Imaging Alghero September 27 2014 index motivation amp introduction. Norm D. Smith, M.D.. Associate Professor. Co-Director. Urologic Oncology. University of Chicago. United States Preventive Services Task Force (USPSTF). USPSTF Warns Against Blood Test For Prostate Cancer. . Julian Mander . RPH Urology. of the Prostate Gland. Dr. . Kaveh. . Mehravaran. Urologist, Fellowship of . Endourology. & Laparoscopy. Hasheminejad. Hospital. BENIGN PROSTATIC HYPERPLASIA. Incidence & . Epidemiology. BPH is the most common benign tumor in men, and . This program will include a discussion of investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a . CÉSAR DAVID VERA-DONOSO. Department. of . Urology. WHO IS IN THE LINE OF FIRE?. WE NEED TO COLLABORATE IN MANY FIELDS. WE NEED RELIABLE IMAGES TO TAKE DECISIONS. INCIDENCE. EUROPE. In Europe, . PCa. The second most common cancer diagnosed in men. The incidence increase with age very rare before age of 40, more in western countries particularly Scandinavian countries (low light exposure), and black men are at greatest risk. When to Image Based on . Choosing . Wisely. ®. . and ACR Appropriateness . Criteria. ®. What Is R-SCAN?. 2. C. ollaborative activity . for referring clinicians and radiologists to improve patient . If you decide not to get screened, you can always change your mind later. If you decide to get screened, it does not mean you have to go to the next step. You should discuss each step with your docto No significant relationship exists between the authors and the compa-nies/organizations whose products or services may be referenced inthis article. Abbreviations used in this paper:CT = computed tomo Latest developments. . Prof.. . Neeraj Agarwal, MD. Director, Genitourinary Oncology Program, . Huntsman Cancer Institute, University of Utah, USA. MARCH 2022. PARPi. , poly-ADP ribose polymerase inhibitors. Victoria . Sinibaldi. , RN, MS, CS, CANP, BC. Daniel P . Petrylak. , MD. . Disclosures for . Ms. . Sinibaldi. No financial interests or affiliations to disclose. Disclosures for Dr . Petrylak. Consulting Agreements. Dr Marie-Pier St-Laurent, MD, FRCSC. Urologic-Oncology fellow, UBC. Research scientist, Vancouver Prostate Centre. Honorarium: Bayer, PCSC. As a urologist, I am biased towards prostate cancer screening.. nm. crpc and the implications of new . imaging modalities. Alexander Drzezga MD, PhD. Professor and Chair . Department of Nuclear Medicine, University Hospital of Cologne, Germany. David Pfister MD, PhD. Session Objectives. Updates of the Status of Research Effort. Evaluation of Biomarker Development Status. Imaging and Urine Testing to Enhance Prostate Cancer Detection. Martin . Sanda. , M.D., Emory University. CVC.